Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
02 December 2022 - 11:00PM
Business Wire
Event to be webcast on Sunday, December 11,
2022 at 9:00 a.m. EST
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for cancer, today announced that the Company will host a
webcast presentation on Sunday, December 11, 2022 at 9:00 a.m. EST
to discuss the most recent data-cut from its ongoing Phase 1 study
evaluating the safety and tolerability of ADI-001 for the potential
treatment of relapsed or refractory B-cell NHL.
The event will feature Sattva Neelapu, M.D., Professor in the
Department of Lymphoma-Myeloma, Division of Cancer Medicine at The
University of Texas MD Anderson Cancer Center, alongside members of
the Adicet management team.
Conference Call and Webcast Event
The live webcast of the presentation can be accessed by
registering under “Presentations & Events” in the investors
section of the Company’s website at https://www.adicetbio.com. Upon
registration, all participants will receive a confirmation email
with a unique passcode to provide access to the webcast event. To
participate via telephone, please join by dialing 1-833-548-0276
(domestic) or 1-646-876-9923 (international) and referencing the
conference ID 98173615816.
An archived replay will be available for 30 days following the
presentation. The archived webcast will be available on the
Company's website beginning approximately two hours after the
event.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma
delta T cells, engineered with chimeric antigen receptors (CARs)
and adaptors (CAds), to enhance selective tumor targeting and
facilitate innate and adaptive anti-tumor immune response for
durable activity in patients. For more information, please visit
our website at https://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221201006019/en/
Adicet Bio., Inc. Investor and Media Contacts
Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Feb 2024 to Mar 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Mar 2023 to Mar 2024